These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 22078570)

  • 1. Improving blood safety and patient outcomes with pathogen reduction technology.
    Goodrich RP; Ettinger A; Radziwon PM; Rock G
    Transfus Apher Sci; 2011 Dec; 45(3):229-38. PubMed ID: 22078570
    [No Abstract]   [Full Text] [Related]  

  • 2. [Pathogen inactivation of platelets: organization consequences for platelet transfusion].
    Chavarin P; DePutter C; Boussoulade F; Acquart S; Vidal M; Argaud C; Fabrigli P; Garraud O
    Transfus Clin Biol; 2011 Aug; 18(4):472-7. PubMed ID: 21783400
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Pathogen reduction: a clinician view].
    Socié G
    Transfus Clin Biol; 2011 Aug; 18(4):491-2. PubMed ID: 21715208
    [No Abstract]   [Full Text] [Related]  

  • 4. Prepare for occupational bloodborne pathogen exposure.
    Harty-Golder B
    MLO Med Lab Obs; 2009 Apr; 41(4):40. PubMed ID: 19456064
    [No Abstract]   [Full Text] [Related]  

  • 5. Pathogen reduction: state of reflection in Ireland.
    Murphy WG
    Transfus Clin Biol; 2011 Aug; 18(4):488-90. PubMed ID: 21803629
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Pathogen inactivation technologies: a complex but necessary debate].
    Andreu G; Cazenave JP; Garraud O; Lefrère JJ
    Transfus Clin Biol; 2011 Aug; 18(4):443. PubMed ID: 21783399
    [No Abstract]   [Full Text] [Related]  

  • 7. Evolution of microbial safety.
    Barbara JA
    Hematol J; 2004; 5 Suppl 3():S69-73. PubMed ID: 15190282
    [No Abstract]   [Full Text] [Related]  

  • 8. Pathogen Reduction Technology in Transfusion: Where Do We Stand?
    Khurshid M; Moiz B
    J Coll Physicians Surg Pak; 2015 Nov; 25(11):779-80. PubMed ID: 26577959
    [No Abstract]   [Full Text] [Related]  

  • 9. [Pathogen reduction of blood components: from financial issues to possible long-term consequences].
    Canellini G; Wasserfallen JB; Tissot JD
    Transfus Clin Biol; 2011 Aug; 18(4):493-7. PubMed ID: 21719339
    [TBL] [Abstract][Full Text] [Related]  

  • 10. OSHA interprets bloodborne pathogens standard.
    Morgenstern TF; Millstein M
    J N J Dent Assoc; 1993; 64(1):9, 11-2. PubMed ID: 8151337
    [No Abstract]   [Full Text] [Related]  

  • 11. Clinical trials for pathogen reduction in transfusion medicine: a review.
    McClaskey J; Xu M; Snyder EL; Tormey CA
    Transfus Apher Sci; 2009 Dec; 41(3):217-25. PubMed ID: 19793679
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Integrating the Occupational Safety & Health Administration mandates on bloodborne pathogens in the practice setting.
    Williams HF
    J Intraven Nurs; 1995; 18(6 Suppl):S9-16. PubMed ID: 8714926
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Pathogen reduction for platelets: a debate].
    Moncharmont P; Py JY
    Transfus Clin Biol; 2011 Aug; 18(4):498-501. PubMed ID: 21715209
    [No Abstract]   [Full Text] [Related]  

  • 14. Contractors' 'band-aid' remedies may defy bloodborne pathogen risks.
    Keesing H
    Occup Health Saf; 1994 Dec; 63(12):49, 51-2. PubMed ID: 15655991
    [No Abstract]   [Full Text] [Related]  

  • 15. Residual risks of blood transfusion in Rhode Island.
    Sweeney JD; Kurtis J; Starakiewicz J
    Med Health R I; 2005 Jul; 88(7):224-5, 228-31. PubMed ID: 16184827
    [No Abstract]   [Full Text] [Related]  

  • 16. No excuse for unsafe injection practices.
    McCrea MK
    AORN J; 2013 Jan; 97(1):132-5. PubMed ID: 23265655
    [No Abstract]   [Full Text] [Related]  

  • 17. Worth the cost?
    Ortolon K
    Tex Med; 2004 Jan; 100(1):43-5. PubMed ID: 15146771
    [No Abstract]   [Full Text] [Related]  

  • 18. [Expected limits (and possible consequences) of pathogen inactivation technology].
    Lefrère JJ
    Transfus Clin Biol; 2011 Aug; 18(4):468-71. PubMed ID: 21802331
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Pathogen inactivation in platelet concentrates: the French experience].
    Cazenave JP
    Transfus Clin Biol; 2011 Aug; 18(4):478-84. PubMed ID: 21719338
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Emily Cooley Memorial Award. Managing change to improve transfusion safety.
    AuBuchon JP
    Transfusion; 2004 Sep; 44(9):1377-83. PubMed ID: 15318865
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.